C4 Therapeutics Statistics
Total Valuation
C4 Therapeutics has a market cap or net worth of $349.27 million. The enterprise value is $112.16 million.
Important Dates
The next confirmed earnings date is Tuesday, May 12, 2026, before market open.
| Earnings Date | May 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
C4 Therapeutics has 110.18 million shares outstanding. The number of shares has increased by 19.49% in one year.
| Current Share Class | 110.18M |
| Shares Outstanding | 110.18M |
| Shares Change (YoY) | +19.49% |
| Shares Change (QoQ) | +60.94% |
| Owned by Insiders (%) | 1.21% |
| Owned by Institutions (%) | 51.40% |
| Float | 79.36M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.72 |
| Forward PS | 20.96 |
| PB Ratio | 1.20 |
| P/TBV Ratio | 1.36 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.12 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.81, with a Debt / Equity ratio of 0.23.
| Current Ratio | 7.81 |
| Quick Ratio | 7.60 |
| Debt / Equity | 0.23 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -44.44% and return on invested capital (ROIC) is -21.83%.
| Return on Equity (ROE) | -44.44% |
| Return on Assets (ROA) | -18.43% |
| Return on Invested Capital (ROIC) | -21.83% |
| Return on Capital Employed (ROCE) | -32.05% |
| Weighted Average Cost of Capital (WACC) | 16.69% |
| Revenue Per Employee | $345,644 |
| Profits Per Employee | -$1.01M |
| Employee Count | 104 |
| Asset Turnover | 0.10 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, C4 Therapeutics has paid $121,000 in taxes.
| Income Tax | 121,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +115.65% in the last 52 weeks. The beta is 2.78, so C4 Therapeutics's price volatility has been higher than the market average.
| Beta (5Y) | 2.78 |
| 52-Week Price Change | +115.65% |
| 50-Day Moving Average | 2.85 |
| 200-Day Moving Average | 2.48 |
| Relative Strength Index (RSI) | 60.57 |
| Average Volume (20 Days) | 2,296,287 |
Short Selling Information
The latest short interest is 21.04 million, so 19.10% of the outstanding shares have been sold short.
| Short Interest | 21.04M |
| Short Previous Month | 16.16M |
| Short % of Shares Out | 19.10% |
| Short % of Float | 26.51% |
| Short Ratio (days to cover) | 6.94 |
Income Statement
In the last 12 months, C4 Therapeutics had revenue of $35.95 million and -$104.99 million in losses. Loss per share was -$1.27.
| Revenue | 35.95M |
| Gross Profit | 26.97M |
| Operating Income | -104.49M |
| Pretax Income | -104.87M |
| Net Income | -104.99M |
| EBITDA | -102.53M |
| EBIT | -104.49M |
| Loss Per Share | -$1.27 |
Full Income StatementBalance Sheet
The company has $248.54 million in cash and $59.98 million in debt, with a net cash position of $237.12 million or $2.15 per share.
| Cash & Cash Equivalents | 248.54M |
| Total Debt | 59.98M |
| Net Cash | 237.12M |
| Net Cash Per Share | $2.15 |
| Equity (Book Value) | 256.59M |
| Book Value Per Share | 2.65 |
| Working Capital | 225.08M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$98.69 million and capital expenditures -$607,000, giving a free cash flow of -$99.30 million.
| Operating Cash Flow | -98.69M |
| Capital Expenditures | -607,000 |
| Depreciation & Amortization | 1.96M |
| Net Borrowing | n/a |
| Free Cash Flow | -99.30M |
| FCF Per Share | -$0.90 |
Full Cash Flow StatementMargins
Gross margin is 75.03%, with operating and profit margins of -290.68% and -292.08%.
| Gross Margin | 75.03% |
| Operating Margin | -290.68% |
| Pretax Margin | -291.74% |
| Profit Margin | -292.08% |
| EBITDA Margin | -285.23% |
| EBIT Margin | -290.68% |
| FCF Margin | n/a |
Dividends & Yields
C4 Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -19.49% |
| Shareholder Yield | n/a |
| Earnings Yield | -30.06% |
| FCF Yield | -28.43% |
Analyst Forecast
The average price target for C4 Therapeutics is $12.20, which is 284.86% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $12.20 |
| Price Target Difference | 284.86% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 45.71% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
C4 Therapeutics has an Altman Z-Score of -1.96 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.96 |
| Piotroski F-Score | 4 |
